Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: HIV Infections

In brief

Antiretroviral therapy (ART) can reduce HIV to very low levels in the blood, but it cannot cure HIV infection because a small amount of virus remains in cells as a hidden (latent) form. The purpose of this study was to evaluate the safety and efficacy of single dose and multiple dose administration of romidepsin (RMD) in HIV-infected adults.

Key facts

Study ID

NCT01933594

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

59

Starts

2014-05-05

Expected to finish

2018-04-16

Last updated by the study team

2021-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Alabama CRS — Birmingham, Alabama, United States
• UCLA CARE Center CRS — Los Angeles, California, United States
• University of Colorado Hospital CRS — Aurora, Colorado, United States
• Massachusetts General Hospital CRS (MGH CRS) — Boston, Massachusetts, United States
• University of Rochester Adult HIV Therapeutic Strategies Network CRS — Rochester, New York, United States
• Chapel Hill CRS — Chapel Hill, North Carolina, United States
• Ohio State University CRS — Columbus, Ohio, United States
• Penn Therapeutics, CRS — Philadelphia, Pennsylvania, United States
• University of Pittsburgh CRS — Pittsburgh, Pennsylvania, United States
• University of Washington AIDS CRS — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.